Level A· Stronger Clinical EvidenceMeta-analysisPubMed

Intra-articular Stromal Vascular Fraction and Mesenchymal Stem Cell Injections Show Variable Efficacy and Higher Potential Complications Compared to Corticosteroid and Hyaluronic Acid in Treatment of Knee Osteoarthritis:

Han JH., Jung M., Chung K., Moon HS., Jung SH., Byun J.

Meta-analysis with a reported sample of 671 on Knee Osteoarthritis, Osteoarthritis, published in Arthroscopy (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Arthroscopy (2025)
Country
United States
Reported sample size
671
Source database
PubMed
PMID
39914607
DOI
10.1016/j.arthro.2025.01.050
Citations
4

Abstract (original English)

Purpose To evaluate the clinical outcomes of intra-articular stromal vascular fraction (SVF) and adipose-derived mesenchymal stem cell (ASC) injections in patients with knee osteoarthritis through a meta-analysis of randomized clinical trials. Methods PubMed, Embase, the Cochrane Library, and Google Scholar were systematically searched to identify Level I studies that compared the clinical efficacy of SVF or ASC with that of other nonoperative treatments. Clinical scores measured 3, 6, and 12 months postinjection were standardized to pain and functional scales for meta-analysis based on minimal clinically important differences. Follow-up magnetic resonance imaging findings and safety-related data were also investigated. Results Nine studies involving 671 patients were included. SVF demonstrated superior pain and function score improvements compared to saline or hyaluronic acid (HA) at 3, 6, and 12 months postinjection. However, SVF was inferior to corticosteroid at 3 months, showed no difference at 6 months, and was comparable or slightly superior at 12 months. ASC consistently showed better pain and function score improvements compared to saline and conservative treatment at all time points, with no significant differences observed compared to HA. High heterogeneity was noted in SVF function score results, requiring cautious interpretation. No serious adverse events related to

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansOsteoarthritis, KneeHyaluronic AcidRandomized Controlled Trials as TopicInjections, Intra-ArticularMesenchymal Stem Cell TransplantationAdrenal Cortex HormonesTreatment OutcomeViscosupplementsAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research